Intellia Therapeutics Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone, and welcome to the Intellia Therapeutics HAE investor event. At this time, all attendees are in a listen-only mode, and a question-and-answer session will follow the formal presentation. To our analysts joining us live, please use the raise hand feature under the reactions button at the bottom of your screen to indicate that you have a question, and we kindly ask that you limit yourself to one question and one follow-up. As a reminder, this call is being recorded, and a replay will be made available on the Intellia website following the conclusion of the event. With that, I will now hand the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Intellia Therapeutics.
Please go ahead, Jason. Thank you, operator, and hello, everyone.
Welcome to our investor event focusing on lonvo-z, Intellia's one-time gene editing candidate for people living with hereditary angioedema. This webcast is taking place in Phoenix, Arizona, at the 2026 American College of Allergy, Asthma & Immunology Scientific Meeting. Just a few moments ago, we issued a press release highlighting our seven presentations at this congress. You can access the press release on the investors and media section of Intellia's website at intelliatx.com. The presentations themselves will be available in the scientific publications and presentation section of our website at the start of their respective sessions. At this time, I would like to take a minute to remind listeners that we will make certain forward-looking statements during this event. We ask that you refer to our SEC filings available at sec.gov for a discussion of potential risks and uncertainties.
All information presented on this call is current as of today, and Intellia undertakes no duty to update this information unless required by law. The agenda for today is shown here. Our CEO, Dr. John Leonard, will begin by providing an overview. He'll be followed by Dr. Marc Riedl, Professor of Medicine at UC San Diego and Clinical Director of the HAEA Angioedema Center. He'll share his perspective about HAE, today's standards of care, and the unmet needs that continue to be experienced by many patients. Our Chief Medical Officer, Dr. Jing Marantz, who joined Intellia last month, will then provide insights about the new clinical data we're presenting at this week's congress. Dr. Danny Cohn of the Amsterdam University Medical Center will share perspective from patients who received lonvo-z and his own personal experience as an investigator in our clinical trials.
Our Senior Vice President of Commercial, Maria Natale, will then share additional color about our market opportunity, the interest we're seeing in lonvo-z among patients, physicians, and payers, and our commercial readiness efforts. Following this, we'll take questions from the audience. With that, let me turn things over to our President and Chief Executive Officer, John Leonard.
Thank you, Jason, and good morning, everyone. We are really excited to share additional clinical data, hear insights from two of the world's leading key opinion leaders in HAE, and for the first time, allow you to get some perspective from patients who have received lonvo-z. We will also highlight some of our new market research, share our view of the market opportunity, and discuss our preparations to launch the world's first in vivo CRISPR-based medicine. Let's start with some broader context about our ongoing work at Intellia Therapeutics. Our goal has been to translate the promise of in vivo gene editing into transformative treatments for people living with severe diseases. Intellia's leadership by the numbers is encapsulated here. As of today, we have dosed more than 600 patients with our investigational in vivo gene editing therapies. We believe this is more than all other companies in the world combined.
We have up to six years of follow-up on some of these patients, and very importantly, we have yet to see any waning of pharmacodynamic or clinical effect. Earlier this year, we reported positive data for lonvo-z from HAELO, and we have two additional phase III trials ongoing for nex-z and transthyretin amyloidosis. On the right, you can see that Intellia's clinical and scientific leadership has been recognized repeatedly in the New England Journal of Medicine. Our pioneering work began more than a decade ago, and we have accomplished a series of world-first milestones in rapid succession since that time. From our first patient dosed in 2020 to the initiation of phase III development in 2024 to our positive readout in HAELO. Our excitement continues to grow as we approach what would be our most important world-first milestone, lonvo-z's expected approval.
As we announced in September, the FDA accepted our biologics license application, or BLA, for lonvo-z and granted it Priority Review. The agency set a PDUFA action date of March 10, 2027, and it also stated that it did not currently plan to hold an advisory committee meeting to discuss the application. We believe lonvo-z is not only well-positioned to receive FDA approval, we also expect it to be a commercial success. This would set it apart from most one-time treatments that have been approved for other indications in the past. While AAV and ex vivo gene editing therapies have represented significant scientific advances, they brought with them a range of inherent limitations and challenges in the real world, some of which are listed here. These realities meaningfully reduce the eligible patient pool, their perceived clinical benefit, and the willingness to prescribe by doctors or receive the therapy by patients.
All one-time therapies are not created equally, and lonvo-z is a one-time treatment unlike any other. We simply don't face these same limitations. Leveraging a combination of CRISPR gene editing, lipid nanoparticles, and an in vivo delivery approach, lonvo-z was intentionally designed to avoid each of the challenges listed here. As a result, we think it will be among the first one-time treatments to actually deliver on the promise of one-time treatments. With that as a backdrop, let's outline four themes for our event today. First and foremost, if approved, lonvo-z will stand alone in the HAE space. Today, patients are served by chronically dosed long-term prophylactic medications, or LTPs, and by on-demand medications that are taken as needed. Lonvo-z is being developed as a one-time therapy that's intended to eliminate both attacks and the need for lifelong treatment. This is our definition of a disruptive therapy.
Second, you will hear loud and clear today that the HAE community is highly informed, engaged, and empowered. Patients play a large and important role in making treatment decisions, and our HAELO enrollment and market research clearly show that patients want lonvo-z. Third, preparations are well underway for potential approval and our planned launch. We have a strong commercialization strategy in place. We already have hired and onboarded our full field team, and wheels are in motion to educate HCPs, build our treatment network, and ensure broad patient access. Finally, we believe lonvo-z is well-positioned to deliver value to all stakeholders, patients, doctors, payers, and investors, once it is approved. Of course, it all begins with the patient. Before we turn to the clinical discussion, let's pause and hear about one person's journey with lonvo-z.
Matt is a patient living in the U.K. who received a one-time treatment in our phase I/II trial back in July of 2023.
I had HAE all of my life, although I didn't know that until I was diagnosed till I was 24. I am 53 now. Pre-diagnosis, I spent a lot of time in and out of hospital when I was young because they just didn't know what it was. It was such a rare disorder. That obviously impacted home life, going out with my friends, and the impact on my parents, missing school days, which again impacted my parents. I was given medication, and the attacks did become less frequent, but they didn't cease. It was much of the same, but just less frequent. It still impacted everybody. It still impacted my wife and where we could go, and whether I'd have to take medication with me or icatibant injections, et cetera. So, no way of predicting when the attacks were going to happen.
It sort of has a mental impact on you because you do become a little bit fearful of being abroad, for example. At the time, obviously, I didn't know anything particularly about it. It was a very new thing to me. It wasn't a case of a new medication taken over, which was then I'd be on for the rest of my life. There was lots of information to read through in terms of before making a decision. They obviously said that it was new, so there was no long-term data with regards to the infusion, and they were very thorough in terms of explaining how the infusion took place through speaking to my family. So, I went into it with my eyes open. Since I've had the infusion of medication that I received, my attacks stopped.
I have not had one attack, not even a mild attack, and I had the infusion two and a half years ago now. I am not on any medication. I think after the infusion, you are still fearful that you are going to have an attack because you do not know whether it has worked or not. But as the weeks go by and the months go by, you have had a whole year without an attack and not on any medication, then you start to believe that you are never going to have an attack again. I am very thankful that I decided to have the infusion. Physically, there is not really much to talk about physically after the infusion because I have not had any attacks. I would like to say a massive thank you to all of the scientists and all the people who work in the laboratories at Intellia.
It is stories like these that motivate all of us at Intellia each and every day. Now let us hear more from Dr. Riedl. He will share some perspective about how treatment decisions are made and some of the unmet needs and burdens that many patients are still facing.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
21 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
